Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Risk model for clinically relevant neutropenic event among patients with non hematological tumors receiving chemotherapy regimens not classified as high-risk for febrile neutropenia: results from a multicenter prospective cohort study (NEURISK)

Date

09 Oct 2016

Session

Poster display

Presenters

Jose Munoz-Langa

Citation

Annals of Oncology (2016) 27 (6): 497-521. 10.1093/annonc/mdw390

Authors

J. Munoz-Langa1, P. Borrega2, J.M. García-Bueno3, P. Purificación Martínez del Prado4, J.M. Campos5, M. Quindos6, R. López Castro7, V. Valentí Moreno8, E. Jiménez Orozco9, M. Lazaro10

Author affiliations

  • 1 Medical Oncology, Hospital Universitari i Politècnic La Fe, 46026 - Valencia/ES
  • 2 Medical Oncology, Hospital San Pedro Alcántara, Alcántara/ES
  • 3 Medical Oncology, Complejo Hospitalario Universitario de Albacete, Albacete/ES
  • 4 Medical Oncology, Hospital de Basurto, Bilbao/ES
  • 5 Medical Oncology, Hospital Arnau de Vilanova, Valencia/ES
  • 6 Medical Oncology, Complejo Hospitalario Arquitecto Marcide-Prof. Novoa Santos, A Coruna/ES
  • 7 Medical Oncology, University Hosptial de Valladolid, Valladolid/ES
  • 8 Medical Oncology, Hospitasl Santa Tecla, Tarragona/ES
  • 9 Medical Oncology, Hospital de Jerez, Jerez de la Frontera/ES
  • 10 Medical Oncology, Complejo Universitario Hospitalario De Vigo, Vigo/ES
More

Resources

Abstract 3187

Background

Primary prophylaxis with G-CSF is not indicated in patients with solid tumors treated with chemotherapy with low or intermediate risk (

Methods

The purpose of this prospective, multicenter study was to develop and validate a risk model to predict the occurrence of CRNE in patients with solid tumors receiving chemotherapy with low or intermediate risk of FN (

Results

The incidence of CRNE was 19.3%. Female gender, metastatic stage, treatment with platinum or anthracyclines-based chemotherapy, and low baseline hemoglobin or neutrophil count were independent predictive factors for CRNE. The accuracy of the model was 82.8% with sensitivity of 24.2%, specificity of 97.7%, positive and negative predictive values (PV) 71.4% and 84.3% respectively. The ROC analysis of training datasets yielded an area under the curve (AUC) of 0.791 (95%CI: 0.729–0.852). A ROC curve plotted for the validation sample yielded similar AUC (0.856; 95%CI: 0.769-0.944), accuracy (85%), Sensitivity (47,4%), Specificity (96.3%), PV+ (75%) and PV- (86.6%).

Conclusions

This model can identify patients at high risk of CRNE before the chemotherapy with low or intermediate risk of FN is started, allowing clinicians an opportunity to plan appropriate and timely neutropenia management.

Clinical trial identification

The number of the trial protocol: AFI-QUI-2011-01

Legal entity responsible for the study

AFIDIO: Asociación para el Fomento de la Investigación y Desarrollo Integral de la Oncología

Funding

AMGEN

Disclosure

All authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings